Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-5232

293T-mouse-BCMA Cell Line

Home » 293T-mouse-BCMA Cell Line

Background of 293T-mouse-BCMA Cell Line

B cell maturation protein (BCMA), also named CD269, is a membrane of the TNF receptor super family (TNFRSF17) and mainly expressed in mature B-lymphocytes, and play an important role in B cell development and autoimmune response. One of the biggest features of BCMA targeted therapy is that it only focuses on one disease, because BCMA is almost not expressed in other tissue cells except on the surface of mature B lymphocytes and plasma cells, but it is highly expressed in all MM cells, and plays a key role in the survival, proliferation, metastasis and drug resistance of MM cells through mediating the downstream signaling pathway. So BCMA is an ideal antigenic target for the treatment of MM.

Specifications

Catalog Number:
KC-5232
Cell Line Name:
293T-mouse-BCMA Cell Line
Clone Number
5-3#
Host Cell Line:
293T
Description:
Stable 293T clone expressing exogenous mouse BCMA gene
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% DMEM + 20% FBS + 10% DMSO
Propagation Medium:
DMEM + 10% FBS + 1μg/mL Puromycin
Selection Marker:
Puromycin
Morphology:
Epithelial
Subculture:
Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 30 hours
Mycoplasma Status:
Negative
In Vivo Validation:

Cell Line Generation

293T-mouse-BCMA cell line was generated using a lentiviral vector expressing the mouse BCMA sequence.

Characterization

Figure 1: Characterization of mouse BCMA overexpression in the 293T stable clone using FACS(Kyinno, Cat#KB-1514).

Figure 2: Characterization of mouse BCMA in the 293T stable clone using PCR sequencing.

Cell Resuscitation

1. Prewarm culture medium (DMEM supplemented with 10% FBS and 1μg/mL puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:4-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1. Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995ÿ999 (2000).
2. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020 Sep 17;13(1):125. doi: 10.1186/s13045-020-00962-7. PMID: 32943087; PMCID: PMC7499842.
3. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13. PMID: 32055000; PMCID: PMC7214244.
4. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD Jr, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun.2024 Jan 19;15(1):615. doi: 10.1038/s41467-024-44873-4. PMID: 38242888; PMCID:PMC10798961.